» Articles » PMID: 28447733

Gene Expression Profile in Human Induced Pluripotent Stem Cells: Chondrogenic Differentiation In vitro, Part B

Overview
Journal Mol Med Rep
Specialty Molecular Biology
Date 2017 Apr 28
PMID 28447733
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The development of human induced pluripotent stem cells (hiPSCs) is considered a turning point in tissue engineering. However, more data are required to improve understanding of key aspects of the cell differentiation process, including how specific chondrogenic processes affect the gene expression profile of chondrocyte‑like cells and the relative value of cell differentiation markers. The main aims of the present study were as follows: To determine the gene expression profile of chondrogenic‑like cells derived from hiPSCs cultured in mediums conditioned with HC‑402‑05a cells or supplemented with transforming growth factor β3 (TGF‑β3), and to assess the relative utility of the most commonly‑used chondrogenic markers as indicators of cell differentiation. These issues are relevant with regard to the use of human fibroblasts in the reprogramming process to obtain hiPSCs. Human fibroblasts are derived from mesoderm and thus share a wide range of properties with chondrocytes, which originate from the mesenchyme. The hiPSCs were obtained from human primary dermal fibroblasts during a reprogramming process. Two methods, both involving embryoid bodies (EB), were used to obtain chondrocytes from the hiPSCs: EBs formed in the presence of a chondrogenic medium with TGF‑β3 (10 ng/ml) and EBs formed in a medium conditioned with growth factors from HC‑402‑05a cells. Based on reverse transcription-quantitative polymerase chain reaction analysis, the results demonstrated that hiPSCs are capable of effective chondrogenic differentiation, with the cells obtained in the HC‑402‑05a medium presenting with morphological features and markers characteristic of mature human chondrocytes. In contrast, cells differentiated in the presence of TGF‑β3 presented with certain undesirable hypertrophic characteristics. Several genes, most notably runt‑related transcription factor 2, transforming growth factor β2 and transforming growth factor β3, were good markers of advanced and late hiPSC chondrogenic differentiation, whereas transforming growth factor β3I, II, III receptors and bone morphogenetic protein-2, bone morphogenetic protein-4 and growth differentiation factor 5 were less valuable. These findings provide valuable data on the use of stem cells in cartilage tissue regeneration.

Citing Articles

Advances in cartilage tissue regeneration: a review of stem cell therapies, tissue engineering, biomaterials, and clinical trials.

Skoracka J, Bajewska K, Kulawik M, Suchorska W, Kulcenty K EXCLI J. 2024; 23:1170-1182.

PMID: 39391058 PMC: 11464958. DOI: 10.17179/excli2024-7088.


Induced pluripotent stem cells in cartilage tissue engineering: a literature review.

Owaidah A Biosci Rep. 2024; 44(5).

PMID: 38563479 PMC: 11088306. DOI: 10.1042/BSR20232102.


Gene expression profile in human induced pluripotent stem cells: Chondrogenic differentiation in vitro, part A.

Suchorska W, Augustyniak E, Richter M, Trzeciak T Mol Med Rep. 2017; 15(5):2387-2401.

PMID: 28447755 PMC: 5428238. DOI: 10.3892/mmr.2017.6334.

References
1.
Sommer A, Rozelle S, Sullivan S, Mills J, Park S, Smith B . Generation of human induced pluripotent stem cells from peripheral blood using the STEMCCA lentiviral vector. J Vis Exp. 2012; (68). PMC: 3499070. DOI: 10.3791/4327. View

2.
Chen G, Deng C, Li Y . TGF-β and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci. 2012; 8(2):272-88. PMC: 3269610. DOI: 10.7150/ijbs.2929. View

3.
Komori T . Regulation of bone development and extracellular matrix protein genes by RUNX2. Cell Tissue Res. 2009; 339(1):189-95. DOI: 10.1007/s00441-009-0832-8. View

4.
Spater D, Hill T, OSullivan R, Gruber M, Conner D, Hartmann C . Wnt9a signaling is required for joint integrity and regulation of Ihh during chondrogenesis. Development. 2006; 133(15):3039-49. DOI: 10.1242/dev.02471. View

5.
Suchorska W, Augustyniak E, Lukjanow M . Genetic stability of pluripotent stem cells during anti-cancer therapies. Exp Ther Med. 2016; 11(3):695-702. PMC: 4774348. DOI: 10.3892/etm.2016.2993. View